Overview
- The PRESERVE‑003 Stage 1 update presented at the IASLC World Conference in Seoul reported median overall survival of 18.5 months for gotistobart versus 10.0 months for docetaxel with a hazard ratio of 0.572.
- Trial investigators and BioNTech said the safety profile remained consistent and manageable with no new safety signals observed in the updated analysis.
- Gotistobart is an anti‑CTLA‑4 antibody engineered to deplete regulatory T cells in the tumor microenvironment, and pharmacokinetic analyses showed higher steady‑state exposure and an exposure–response link that supports the chosen dose.
- The companies will proceed into the pivotal Stage 2 portion of PRESERVE‑003, but the larger randomized readout will be required to confirm efficacy and determine regulatory and clinical impact.
- If the pivotal data confirm the benefit, gotistobart could offer a chemotherapy‑free option for heavily pretreated patients with metastatic squamous non‑small cell lung cancer and would bolster BioNTech's shift toward an oncology business while leadership and portfolio changes continue.